Sarepta Therapeutics (SRPT) stock is getting crushed in pre-market trading Monday, down 8 points, or 33.79%, after the company said in a press release that the U.S. Food and Drug Administration has asked for more information on its experimental muscular dystrophy treatment, suggesting that a filing for that drug will be pushed back into mid-2015 […]
View the full post at: Morning Buzz: Sarepta Therapeutics (SRPT), Hewlett-Packard Company (HPQ), Tesla Motors (TSLA), Twitter (TWTR), Alibaba Group (BABA)